Stockholm, Sweden, October 1, 2018 – The shareholders of IRRAS AB (“IRRAS”), a commercial-stage medical-technology company focused on developing and commercializing innovative solutions for various brain pathologies, voted to approve Eva Nilsagård as new member of the Group’s board of directors at today’s extraordinary shareholders’ meeting.
Nilsagård has an impressive background in finance and business development, including Finance Manager at SKF AB, Senior Vice President of strategy and business development at Volvo AB and various finance rolls at Astra Tech, a former unit of AstraZeneca focusing on dental implants and other medical devices for urology and surgery. She has also been CFO at Plastal Industri AB and Vitrolife AB.
Nilsagård is currently on the board of Svensk Exportkredit, AddLife and Bufab and she is chairman of the audit committee of AddLife and a member of the audit committee of Svensk Exportkredit and Bufab.
“I’m very excited to join the board of IRRAS. As an innovative medical device maker, the IRRAS products have the potential to save thousands of lives,” said Eva Nilsagård. “I look forward to helping IRRAS to establish IRRAflow as the standard of care in intracranial bleedings, and continue to innovate dependable solutions for neurocritical care medical professionals around the world.”
“Eva is an important addition to our board and we are eager to have her join us as we look toward establishing IRRAS’ position as an innovative company with transformative products. Her strong financial background is exactly the type of experience we need to help take IRRAS to the next level,” said Chairman Anders P. Wiklund.
For more information, please contact:
Fredrik Alpsten
CFO and Deputy CEO
+46 706 67 31 06
fredrik.alpsten@irras.com
About IRRAS
IRRAS AB (Nasdaq First North Premier: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on developing and commercializing innovative solutions for brain surgery. The company’s initial product, IRRAflow®, addresses the complications associated with the current methods of managing intracranial fluid by using a dual lumen catheter that combines active irrigation with ongoing fluid drainage. IRRAflow received FDA clearance in July 2018.
Regularly during treatment, the IRRAflow catheter is automatically flushed to prevent common catheter occlusions from forming. Because IRRAflow is a completely closed system, it is designed to reduce the documented infection risk of these procedures. Additionally, IRRAflow incorporates ICP monitoring and uses a proprietary software to regulate treatment based on desired pressure levels.
With its unique product portfolio, protected by property patents and patent applications, IRRAS is well positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB is listed on Nasdaq First North Premier. Wildeco is certified adviser of the company.
The information was released for public disclosure, through the agency of the contact person above, on October 1, 2018 at 11.00 a.m. (CET).
